50 results
Does dexamethason reduce the levels of plasma inflammatory proteins in patients undergoing coronary artery bypass graft (CABG) surgery who have a normal or disturbed ejection fraction such that proapoptotic pathways are inhibited?Does a…
To determine the antileukemic activity of combination chemotherapy including bortezomib as reinduction therapy in childhood relapsed/refractory ALL.
Primary Objective: Comparison of incidence of post-cataract extraction ocular inflammation with subconjunctival steroid injection versus traditional eye drops.Secondary Objective: Evaluation of usefulness of physostigmine following cataract surgery.
This study will investigate whether oligometastatic triple negative or BRCA1/2 related breast cancer can be treated effectively with a multimodality approach including induction chemotherapy, and whether high dose alkylating chemotherapy can improve…
To assess the bioequivalence of 6 mg dexamethasone tablet administered PO as an alternative to 5,26 mg dexamethasone-disodiumphosphate (= 4 mg dexamethasone) solution administered IV
The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…
To compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs PFS in subjects receiving Rd alone.
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
Given the medical need for improved treatment strategies for patients with previously treated and relapsed MM, the purpose of this phase III study is to compare treatment with bortezomib/dexamethasone + panobinostat to bortezomib/dexamethasone +…
The primary objective is to compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM). Secondary objectives…
GACHE aims to evaluate the effect on morbidity and mortality of early adjuvantcorticosteroids (dexamethasone) in the treatment of adult patients with HSVE. The major motivation for this trial is the extremely unsatisfactory outcome of patients…
Nearly all patients who die from breast cancer die from the consequences of distant metastases. Adjuvant chemotherapy, either administered before or after surgery, has been shown to reduce the risk of metastases and death. Four main groups of…
To assess whether a single shot of dexamethasone reduces postoperative pain, and reduces the time children need to start with drinking and eating.
This study examines if there are therapeutic benefits over injecting dexamethason into the temporomandibular joint after arthrocentesis with patients with ostheoarthritis.
In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antiemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed CINV induced by non-AC based…
We plan to conduct a large, pragmatic, multicentre, randomised non-inferiority trial to determine whether the use of intraoperative dexamethasone, a widely used antiemetic in perioperative medicine, is associated with an unacceptable increased risk…
As of protocol Amendment 06, evaluation of the safety profile of MLN9708 and/or other study medication is the only endpoint being assessed. All other study endpoints will no longer be assessed.
This study will investigates the effect of high dose alkylating chemotherapy compared to standard dose chemotherapy as part of a multimodality approach in patients with oligometastatic HRD positive and/or BRCA1/2 related breast cancer.
The study will look at patients with relapsed (returned after prior treatment) and refractory (not responsive to prior treatment) multiple myeloma. The research aims to compare a new drug called elotuzamab combined with standard of care (…
This phase II/III controlled multicenter trial will investigate the ability of individualized chemotherapy to improve the objective response rate of *triple-negative* breast cancer (estrogen receptor and progesterone receptor-negative, no HER2…